H Lundbeck

Q1: A decent start to the year

13/05/22 -"Lundbeck has started the year on a decent note. While sales declined in constant currency terms, this had largely been expected due to Northera’s patent expiry. Encouragingly, substantial growth ..."

PDF page sample
Pages
54
Language
English
Published on
13/05/22
Download
You may also be interested by these reports :
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...
18/11/25
Over past eighteen months, there has been a glaring performance divergence for family-owned Ipsen (BUY; France) vs. AV Small Pharmas. While the ...
17/11/25
Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO